Carl Zeiss Meditec has introduced a trifocal IOL (AT LISA tri 839MP), although it is not available for use in the United States.
Jena, Germany-Carl Zeiss Meditec has introduced a trifocal IOL (AT LISA tri 839MP), although it is not available for use in the United States.
Based on a proprietary platform (AT LISA), the trifocal implant is designed to produce satisfying and predictable visual outcomes, as well as maximized pupil independency, in active patients. The IOL features asymmetrical light distribution between the three different foci: 50% far, 20% intermediate, and 30% near.
According to Carl Zeiss Meditec, the new IOL supports ophthalmologists and ophthalmic surgeons in meeting the demands of patients with cataract and presbyopia who lead active lives and expect surgery to provide them with a quality of vision that is similar to what they were used to before the aging process of their eyes started.
“We would like to assist our customers in optimally addressing the challenges of surgical cataract and presbyopia correction,” said Ludwin Monz, PhD, president and chief executive officer of Carl Zeiss Meditec AG. “With the [new] trifocal IOL, this means that patients are provided with the most natural postoperative vision possible without being reliant on eyeglasses.”
According to Carl Zeiss Meditec, the trifocal IOL can provide enhanced intermediate vision performance with its addition of +1.66 D compared with apodized bifocal or convoluted trifocal IOLs, even under poor light conditions. The pre-loaded implant is suitable for microincision cataract surgery.
For more information, visit www.meditec.zeiss.com/lisa-tri.
For more articles in this issue of Ophthalmology Times eReport, click here.